Equities
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
More ▼

Profile data is unavailable for this security.

About the company

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

  • Revenue in USD (TTM)6.15bn
  • Net income in USD1.47bn
  • Incorporated2012
  • Employees10.00k
  • Location
    Zoetis Inc10 Sylvan WayPARSIPPANY 07054-3825United StatesUSA
  • Phone+1 (973) 822-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.zoetis.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ZTS:NYQ since
announced
Transaction
value
ZNLabs LLCDeal completed22 Nov 201922 Nov 2019Deal completed16.59%--
Phoenix Central Laboratory For Veterinarians IncDeal completed31 Oct 201931 Oct 2019Deal completed9.84%--
Platinum Performance IncDeal completed22 Jul 201922 Jul 2019Deal completed22.85%--
Data delayed at least 15 minutes, as of Jan 17 2020 23:30 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.